Novel Platinum Complexes

We are developing new formulations of the dinuclear-platinum complex, CT-3610. This novel molecule is more potent than cisplatin, endowed with a unique mechanism of action, active in preclinical studies on a large panel of tumor models, sensitive and refractory to cisplatin and has a safety profile comparable to that of cisplatin.

To prevent undesirable metabolism of the molecule and irreversible protein binding in human plasma, we are developing innovative drug delivery systems. Initial experimentation has demonstrated that nanoparticle formulations of CT-3610 improve the pharmacokinetic profile of the drug. This results in a decrease of the rate and extent of irreversible interaction with plasma proteins and potentially higher free drug concentrations in the tumor.

We also are working on novel bis-platinum analogues rationally designed and synthesized to have improved biopharmaceutical properties that reduce the intrinsic reactivity of the molecule and that demonstrate preclinical antitumor efficacy in solid tumor models.


Posted Jan. 24, 2006

Copyright © 2004-2007 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.